- Open Access
Sexually dimorphic metabolic responses mediated by CRF2 receptor during nutritional stress in mice
Biology of Sex Differencesvolume 9, Article number: 49 (2018)
Chronic stress is a major contributor in the development of metabolic syndrome and associated diseases, such as diabetes. High-fat diet (HFD) and sex are known modifiers of metabolic parameters. Peptide hormones corticotropin-releasing factor (CRF) and urocortins (UCN) mediate stress responses via activation and feedback to the hypothalamic-pituitary-adrenal (HPA) axis. UCN3 is a marker of pancreatic β-cell differentiation, and UCN2 is known to ameliorate glucose levels in mice rendered diabetic with HFD. CRF receptor 2 (CRF2) is the only known cognate receptor for UCN2/3. Here, we ascertained the role of CRF2 in glucose clearance, insulin sensitivity, and other parameters associated with metabolic syndrome in a mouse model of nutritional stress.
Wild-type (WT) and Crhr2−/− (null) mice of both sexes were fed either normal chow diet or HFD. After 8 weeks, blood glucose levels in response to glucose and insulin challenge were determined. Change in body and fat mass, plasma insulin, and lipid profile were assessed. Histological evaluation of liver sections was performed.
Here, we show that genotype (Crhr2), sex, and diet were all independent variables in the regulation of blood glucose levels, body and fat mass gain/redistribution, and insulin resistance. Surprisingly, CRF2-deficient mice (Crhr2−/−) male mice showed similarly impaired glucose clearance on HFD and chow. HFD-fed female Crhr2−/− mice redistributed their fat depots that were distinct from wild-type females and male mice on either diet. Blood cholesterol and low-density lipoprotein (LDL) levels were elevated significantly in male Crhr2−/− mice; female Crhr2−/− mice were protected. Male, but not female Crhr2−/− mice developed peripheral insulin resistance. HFD, but not chow-fed wild-type male mice developed hepatic macrovesicular steatosis. In contrast, livers of Crhr2−/− male mice showed microvesicular steatosis on either diet, whereas livers of female mice on this 8-week HFD regimen did not develop steatosis.
CRF2 receptor dysregulation is a sexually dimorphic risk factor in development of pre-diabetic and metabolic symptoms.
Stress is a major risk factor in the development of metabolic syndrome and type 2 diabetes [1, 2]. Diabetes is reaching epidemic proportions with nearly 8.3% of global population diagnosed as diabetic [3, 4]. Acute stress responses mobilize body’s energy reserves to cope with the changed energy requirements in the short-term ; however, long-term stress is detrimental to health. Stress responses are coordinated by the corticotropin-releasing factor (CRF) family that comprises four known peptide hormones—CRF and three urocortins (UCN 1–3)—and two G protein-coupled receptors (GPCRs)—CRF1 and CRF2 . CRF2 is encoded by the gene Crhr2 present on chromosome 7 in humans and 6 in mice. CRF is intimately involved in regulation of behavioral and endocrine stress responses by activating the HPA axis via CRF1. Urocortins dampen stress sensitivity via activation of the CRF2. CRF and UCNs are also involved in regulating cardiovascular function [7, 8] and inflammatory responses [9,10,11,12]. Both UCN2 and UCN3 are known to regulate glucose homeostasis in animal models of type 2 diabetes [13, 14]. CRF2 is the main receptor that mediates stress-coping actions of psychological stressors and downregulation of its expression and function is observed during chronic stress .
UCN3 is thought to be a marker for β-cell maturity and function . UCN3 is stored and released with insulin, participating in a negative feedback loop that promotes somatostatin release to ensure timely reduction of insulin secretion . Lack of UCN3 has been linked to excessive insulin release, contributing to the pathophysiology of diabetes . A single intravenous injection of adeno-associated virus encoding urocortin2 (AAV.UCn2) normalized blood glucose in db/db and C57BL/6 mice rendered diabetic with HFD . CRF2 is required to mediate therapeutic effects of UCN2, and null mice for CRF2 (Crhr2−/−) are unable to improve glucose mobilization even in presence of AAV.UCn2 . Thus, CRF2 is crucial in mediating effects of UCN2 and probably UCN3 in glucose homeostasis.
Nutritional excess as seen with intake of calorie-rich foods, contributes to the development of type 2 diabetes and metabolic syndrome. Metabolic syndrome refers to a cluster of abnormalities including impaired glucose metabolism, insulin sensitivity, obesity, and dyslipidemia [16,17,18]. The abnormalities associated with metabolic syndrome are risk factors for cardiovascular diseases and diabetes. In experimental animal models, excess dietary fat consumption contributes to impaired glucose metabolism, leading to development of insulin resistance and hyperglycemia . High-fat diet feeding has been used as a model to induce type 2 diabetes, obesity, and associated phenotypes in mice . Psychological stressors downregulate expression of CRF2 receptors , and CRF2 receptor null mice (Crhr2−/−) are more anxious than wild-type littermates [22, 23]. Psychological stressors also drive sex-specific metabolic disturbances in human population studies , but whether downregulation of CRF2 receptors also drives metabolic disturbances, such as hyperglycemia, insulin resistance, dyslipidemia, and fatty liver associated with nutritional stress, has not been shown. In this study, we asked if impairment of the CRF2 receptor contributed to the development of sex-specific metabolic phenotypes during nutritional stress. To test this hypothesis, we subjected Crhr2−/− and wild-type mice of both sexes to 8 weeks of high-fat diet nutritional stress and evaluated metabolic outcomes.
Here, we report that Crhr2 null male, but not female mice develop impaired glucose tolerance on standard chow. In Crhr2 null male mice, fat redistribution and dyslipidemia contributed to the development of metabolic phenotype and insulin resistance. High-fat diet worsened insulin sensitivity in Crhr2 null male mice alone. Sex, diet, and genotype were all significant variables in both glucose tolerance and insulin sensitivity, suggesting that dysregulation of CRF2 receptor, a key mediator of stress responses, is involved in the development of diabetes and metabolic syndrome.
Materials and methods
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California San Francisco and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Generation of Crhr2−/− (C57BL/6 background) mice has been described previously . Crhr2+/− x Crhr2+/− (heterozygous) mice were bred to obtain wild-type (WT), heterozygous (Crhr2+/−), and knockout (Crhr2−/−) male and female mice as described previously . Littermates of 8–9 weeks of age weighing 18–20 g (female mice) and 25–29 g (male mice) were used in all the studies described. The mice were housed in a room that was temperature (22–25 °C) and light controlled (12-h: 12-h light/dark cycle starting at 7 AM). The mice were fed with a standard chow diet consisting of 9% fat (PicoLab mouse Diet 20 #5058, Lab Supply, Fort Worth, Texas, USA) or high-fat diet (HFD) with 60% kcal fat (Catalog# 12492 Research Diets, NJ USA) for 8 weeks. Mice were group housed with 4–5 mice per cage and provided with enrichment. The entire experiment was repeated once (n = 4–5/group/sex) with a total of n = 8–10/group/sex. At the end of the experiments, mice were euthanized and blood was collected in heparinized 1-ml syringe from the inferior vena cava. Various tissues were collected for analyses.
Mice were weighed twice weekly throughout the duration of the study. Mice were handled consistently by the same researchers (S.P and S-I.H) to minimize handling-related stress. Change in body mass gain per week was calculated by subtracting the baseline value obtained at the start of the study. Percent (%) change in body mass for chow- or HFD-fed mice was calculated using the formula: final weight in g − initial weight in g/initial weight in g × 100 to allow for comparisons between all groups.
Food intake per cage was calculated by dividing the total food intake per cage/week by number of mice/cage and is considered as a good measure of food intake . Since body weight gain showed sexual dimorphism, food intake per mouse was calculated by dividing food intake per cage/average body weight of the mice per cage (g/g bw). Percent (%) difference in food intake was calculated using the formula: |V1 − V2|(V1 + V2)2 × 100 to allow for comparisons between all groups.
Glucose tolerance test (GTT)
WT, Crhr2 heterozygous, and Crhr2 null mice of both sexes were fed with standard chow or HFD for 8 weeks. Intraperitoneal glucose tolerance test (IP-GTT) was conducted to assess the disposal of glucose by measuring glucose level after fasting for 14–16 h. The testing was performed at a fixed time to avoid circadian variations in blood glucose levels. Per day, maximum of two cages of either male or female sex (total of 8–10 mice from two cages) were used to perform GTT or insulin tolerance test. Mice were weighed after fasting, and baseline (pre-injection or time 0 min) level of glucose was measured. Mice were injected ip with 2 g/kg glucose (Sigma, St. Louis, MO, USA), and glucose levels were measured at 30, 60, and 120 min. Blood samples were obtained by tail nick, and glucose levels were monitored using the Alpha Trak2 glucose monitor and strips (Abbotts, USA).
Insulin tolerance test (ITT)
WT, Crhr2 heterozygous, and Crhr2 null mice of both sexes were fasted for 6 h and body weight was recorded. Blood sample was collected by tail nick and baseline (0 min) glucose was measured using the Alpha Trak2 glucose monitor and strips (Abbotts, USA). Mice were injected ip with 0.375 U/kg human insulin (Novolin, Novo Nordisk), and glucose levels were measured at 15, 30, 45, and 60 min after insulin injection.
Insulin assay and plasma lipid profile analysis
Blood was collected in heparinized vials for insulin assay and plasma lipid profile analysis. Plasma insulin was assayed using kit from Mesoscale diagnostics (www.mesoscale.com, USA). Cholesterol, triglycerides, and high-density lipoprotein (HDL) were measured using the Siemens Advia chemistry analyzer (Siemens Healthcare Diagnostics Inc., USA). LDL was calculated using the formula: LDL Cholesterol = Total cholesterol − (HDL Cholesterol + Triglycerides/5).
Tissues were collected and fixed in 4% paraformaldehyde for 14–16 h. Tissues were paraffin embedded, and 4–6 μm sections were cut and stained with hematoxylin-eosin at the Mouse Histology Core Facility, University of California San Francisco. Livers from four to five mice/group were imaged, and six to eight fields/liver were captured. A liver pathologist (Dr. Aras Mattis, MD, PhD), blind to the treatment groups, helped with analysis of liver sections.
We considered genotype, diet, and sex as independent variables. GTT and ITT data was analyzed using repeated-measure analysis of variance (ANOVA) followed by Sidak’s post hoc analysis. For all other outcomes, significant main effects of each variable and their interactions were determined using three-way ANOVA. When significant main effects were present, Tukey’s multiple comparisons were performed. When comparing two groups, Student’s t test was used. A p value < 0.05 was considered significant. All statistical analyses were conducted using the GraphPad Prism 7.0™ software.
Crhr2-deficient male mice gained more body mass than Crhr2−/− female mice
Body mass gain is associated with metabolic syndrome and type 2 diabetes. We determined the contribution of CRF2 receptor (genotype) and sex on body mass gain and food intake. Genotype, sex, and diet were significant independent variables for body weight mass gain and also showed significant interactions (Fig. 1 and Additional file 1). At the end of 8 weeks, WT male mice gained ~ 10% body mass on chow and ~ 47% on HFD (Fig. 1a, c). Crhr2−/− male mice gained ~ 21% body mass on chow and ~ 53% on HFD (Fig. 1b, c). WT female mice gained ~ 20% body mass on chow and ~ 43.6% on HFD (Fig. 1d, f). Crhr2−/− female mice gained only ~ 10% body mass on chow ~ 41% on HFD (Fig. 1e, f), and the body mass gain between chow and HFD in WT and Crhr2−/− female mice was not statistically significant. Crhr2+/− male and female mice also showed significant body mass gain as compared with their chow-fed controls (Additional file 1).
Crhr2-deficient male mice increased chow intake, whereas Crhr2-deficient female mice decreased HFD intake
Genotype, sex, and diet showed significant interaction for food intake (Fig. 2). Male Crhr2−/− mice increased chow intake by 25.71 and 36.89% compared with WT and Crhr2+/− mice (p = 0.0342 and p = 0.0013 respectively, Fig. 2a and Additional file 2). No significant difference in HFD intake in male mice was noted (Fig. 2a). In contrast to male mice, chow intake in female of different genotypes did not differ, whereas female Crhr2−/− consumed 44.67% less HFD compared with WT female mice (p = 0.0004, Fig. 2b).
Crhr2 genotype affected blood glucose levels in a sexually dimorphic manner
To determine the contribution of CRF2 receptor and sex in glucose clearance, we performed GTT and ITT at the end of 8 weeks. Genotype, diet, and sex were all variables in regulation of glucose clearance (Fig. 3). As expected, HFD-fed WT male mice showed an increase in the area under the curve (AUC) compared with chow-fed controls (Fig. 3a, c). Surprisingly, chow-fed Crhr2−/− male mice had AUC that was equivalent to that of HFD-fed Crhr2−/− male mice (Fig. 3b, c). On the other hand, HFD-fed female WT and Crhr2−/− mice showed impaired IP-GTT responses with significantly elevated blood glucose levels and AUC compared to chow-fed controls (Fig. 3d–f). HFD-fed Crhr2+/− (heterozygous) male and female mice also showed significant increases in blood glucose levels and AUC compared to chow-fed controls (Additional file 3).
Crhr2-deficient male mice exhibited impaired insulin sensitivity, whereas female mice were protected
Genotype, diet, and sex were all variables in regulation of insulin sensitivity as evidenced by impaired glucose clearance after a bolus of insulin injection in ITT (Fig. 4a–e). WT male mice on chow and HFD similarly decreased blood glucose levels in ITT (Fig. 4a–c). HFD-fed Crhr2−/− male mice had significantly elevated glucose levels compared to chow-fed Crhr2−/− mice at all time points (Fig. 4b). The AUC was nearly twofold higher in HFD-fed vs. chow-fed Crhr2−/− male mice (p < 0.0001, Fig. 4c). Female Crhr2−/− mice and Crhr2+/− mice of both sexes retained normal glucose responses in ITT (Fig. 4d–f and Additional file 4). Since liver is a major site of insulin action that regulates glucose release, next, we examined whether HFD modulated CRF2 receptor expression in the livers of WT male mice. CRF2 receptor expression increased by ~ 1.5-fold in the livers of HFD-fed mice compared to chow-fed mice (Fig. 4g). Taken together, these data highlight the role of stress receptor, CRF2 in mediating sexually dimorphic peripheral insulin resistance.
Male, but not female mice on HFD have significantly higher plasma insulin levels
As Crhr2 null mice were insulin resistant, we next assessed changes in plasma insulin levels in mice of both sexes in response to HFD consumption. Genotype, sex, and diet were significant independent variables and also showed significant interaction (Fig. 5). Plasma insulin levels were significantly elevated in HFD-fed WT, Crhr2−/−, and Crhr2+/− male mice compared to their respective chow-fed controls (Fig. 5a and Additional file 5). HFD intake did not significantly alter plasma insulin levels in female mice of any genotype compared to chow-fed control mice (Fig. 5b and Additional file 5).
Sex and diet were variables in fat mass gain and/or redistribution
Visceral fat mass gain and/or fat mass redistribution are factors that contribute to metabolic disorder and peripheral insulin resistance. Changes in four different fat types—gonadal (epididymal or ovarian), mesenteric, perirenal, and brown fats—were examined. Sex and diet were variables and showed interaction for fat mass gain (Fig. 6a–h). In male mice, HFD intake did not significantly change gonadal (epididymal) or brown fat mass in WT and Crhr2−/− mice compared to their respective chow-fed controls (Fig. 6a, d). There were significant increases in mesenteric and perirenal fat mass in HFD-fed WT male mice compared to chow-fed controls (Fig. 6b, c). Significant differences in epididymal and perirenal fats were observed between chow- and HFD-fed Crhr2+/− male mice (Additional file 6). In female mice, HFD intake in Crhr2−/− mice resulted in significant fat mass gained in all four types of fats examined compared with chow controls (Fig. 6e–h).
Crhr2-deficient male mice showed dyslipidemia, but female mice were protected
Changes in two or more plasma lipid levels (dyslipidemia) are associated with diagnosis of metabolic syndrome and type 2 diabetes. Plasma lipid panel that included cholesterol, high-density lipoprotein (HDL), and triglycerides was determined using mass spectrometry. Low-density lipoprotein (LDL) levels were calculated as described in methods. Genotype, sex, and diet were significant independent variables in plasma lipid levels and also showed significant interaction (Fig. 7).
In male mice, HFD intake resulted in elevated plasma cholesterol levels by 37.7% in WT, 50.3% in Crhr2+/−, and by 40.9% in Crhr2−/− compared with chow-fed controls (Fig. 7a and Additional file 7a). In female mice, HFD intake did not result in significant increases in plasma cholesterol compared with chow fed controls (Fig. 7b and Additional file 7b).
In male mice, plasma HDL levels increased by 36.1% in WT and by 38.3% in Crhr2+/− compared with chow-fed controls (Fig. 7c and Additional file 7c). In female mice of all three genotypes, plasma HDL levels showed did not differ between chow and HFD (Fig. 7d and Additional file 7d).
In male mice, plasma LDL levels increased by 53.6% in Crhr2−/− and by 68.0% in Crhr2+/− compared with chow-fed controls (Fig. 7e and Additional file 7e). Importantly, HFD-fed Crhr2−/− male mice had approximately twofold higher LDL levels compared with HFD-fed WT mice (Fig. 7e). In female mice, LDL levels did not differ between HFD- and chow-fed mice (Fig. 7f and Additional file 7f).
In male mice of either genotype, triglyceride levels did not differ between HFD vs. chow (Fig. 7g). In female WT and Crhr2−/− mice, triglyceride levels did not differ between HFD vs. chow (Fig. 7h). Interestingly, triglyceride levels in chow-fed Crhr2+/− female mice were significantly higher compared with chow-fed WT and Crhr2−/− (Additional file 7 h).
Crhr2-deficient male mice develop microvesicular liver steatosis
Lipid accumulation in the liver is a characteristic of a myriad of diseases such as type 2 diabetes and metabolic syndrome. H&E-stained sections revealed macrovesicular steatosis in livers of HFD-fed WT male compared with chow-fed controls with fat droplets vacuoles evident (Fig. 8 a, b, arrows). Surprisingly, livers of chow-fed Crhr2−/− male mice exhibited microvesicular steatosis with swollen sinusoids evident (Fig. 8c, arrows) and HFD consumption for 8 weeks did not further worsen liver steatosis in Crhr2−/− male mice (Fig. 8d). In sharp contrast to male mice, chow- or HFD-fed female WT or Crhr2−/− mice did not show any signs of steatosis (Fig. 8e, f).
Chronic stress is known as a factor contributing to the development of metabolic syndrome, type 2 diabetes, and many other pathophysiologies. In this study, we report several novel observations; mice lacking the stress receptor, CRF2, show impaired glucose clearance and microvesicular liver steatosis on standard chow diet in a sexually dimorphic manner. Short-term nutritional stress rendered male mice of Crhr2-deficient genotype insulin resistant and dyslipidemic, whereas female mice of Crhr2 genotype were protected, in the time period examined. CRF2 receptor activation and function is required for feedback to the HPA axis to bring systems back to homeostasis after stress responses. CRF2 receptor dysregulation is reported in chronic stress [21, 26]. Prospective cohort studies have shown that perceived stress increases risk of developing type 2 diabetes in men, but not in women by approximately twofold and a 1.4 higher odds ratio . Our findings that only male mice with Crhr2 genotype, but not female mice develop impaired glucose clearance and other metabolic phenotypes on short-term nutritional stress, is in agreement with clinical reports that men are more prone to developing type 2 diabetes under stressful conditions. Haploinsufficiency of CRF2 may be akin to downregulation of CRF2 receptor under chronic stress conditions and increasing the risk of developing metabolic syndrome and type 2 diabetes.
Male and female mice gained body mass differently on a fat-rich diet. In animal models, male C57BL/6 mice gain significantly more body and fat mass than female mice on HFD . We found that lack or haploinsufficiency of stress receptor, CRF2, rendered male mice even more prone to body and fat mass gain on a fat-rich diet than WT male mice, whereas female mice of Crhr2 genotype were less susceptible to fat-rich diet-induced changes, at least in this short-term nutritional stress model. Since body mass gain was significantly different between the genotypes and sexes, fat mass and food intake were normalized to body mass. On a standard diet, Crhr2 null male mice gained ~ 12% more body mass than WT littermates. The differences in body mass gain between WT and Crhr2 null male mice could be accounted for by increased chow diet intake per week over the 8-week period. On a fat-rich diet, Crhr2 null male mice gained ~ 6% more body mass than WT littermates, but HFD consumption did not differ between the two genotypes. Female mice of either genotype showed increase in body weight on HFD, but the body mass gains were not significantly different from that gained on chow, suggesting that female mice may handle short-term nutritional stress overload better than male mice.
We found genotype and sex as significant modifiers of the effect of diet for several metabolic outcomes. First, only male mice of Crhr2 genotype had worse glucose clearance on standard chow diet. A recent systematic study that characterized effects of sex and body weight on metabolic outcomes on a high-fat diet in C57BL/6 mice found that male mice show worse glucose clearance on high-fat diet than female mice . Furthermore, this published study used nearly 300 mice per sex to characterize metabolic phenotype on breeder’s chow and HFD to create a reference database . Our sexually dimorphic metabolic phenotypes in C57BL/6 mice are in agreement with this reference data bank.
Genotype, diet, and sex also were significant modifiers of peripheral insulin responses. In insulin tolerance studies, only male Crhr2 null mice were hyperglycemic on a fat-rich diet. Blood glucose level remained significantly elevated in HFD-fed Crhr2 null males after insulin injection and throughout the duration of the experiment (60 min), whereas glucose levels returned to baseline in HFD-fed WT male and female mice. We used the lowest possible insulin dose, as female Crhr2−/− mice did not tolerate higher doses of insulin, becoming severely hypoglycemic and had to be given a bolus of glucose. At the end of 8 weeks of fat-rich diet consumption, CRF2 receptor levels increased in livers of WT mice suggesting diet-induced compensation of the stress axis. Others have shown that palatable food intake feeds back to the HPA axis to better cope with stress responses [27, 28]. A combination of low dose of insulin used in ITT, increase in CRF2 receptor levels, and possible association of CRF2 receptor with ancillary proteins  that may differ between the sexes, may explain this sexual dimorphism in metabolic responses to nutritional stress. It might be possible that CRF2 receptor levels show bimodal responses to nutritional stress, with levels increasing during short-term, but decreasing with long-term (> 8 weeks) HFD consumption. Consistent with this notion, bimodal levels of CRF2 receptors have been shown in response to acute vs. chronic inflammatory stress in other experimental animal models .
Enhanced release of glucagon, glycogenolysis, and peripheral insulin resistance may explain hyperglycemia in Crhr2 null mice. Chronic insulin resistance leads to hyperinsulinemia and resulting inactivation of insulin signaling pathways [30,31,32]. In rodent pancreas, paracrine communication between α- and β-cells resulted in insulin-inhibiting glucagon release. Selective inactivation of insulin receptor in pancreatic α-cells is known to upregulate glucagon release . Delivery of anti-insulin antibodies in rat pancreas resulted in increased glucagon release . High blood glucose levels also stimulated glucagon release . Thus, a compromised stress response as in the Crhr2 null mice might worsen metabolic function with higher or dysregulated release of glucagon causing impaired glucose clearance and insulin resistance. The next steps would be to determine insulin and glucagon release from isolated islet cultures from WT and Crhr2−/− mice exposed to different glucose concentrations. The exact mechanism of the insulin-induced hyperglycemia observed in our experimental model is yet to be investigated.
CRF2 receptors are expressed on pancreatic δ-cells and may be involved in the release of somatostatin as well as glucagon from δ- and α-cells, respectively. Somatostatin and glucagon in turn are known regulators of insulin release from β-cells . Thus, CRF2 receptor dysfunction may regulate insulin release via inhibiting somatostatin and glucagon release in a secondary messenger-dependent manner. We have previously shown that CRF2 receptors can alter intracellular concentrations of both cAMP and Ca2+ [29, 37]. We have also shown sexual dimorphism in Ca2+-dependent signaling in pancreatic acinar cells in murine model of acute stress . Furthermore, we have shown that loss of CRF2 receptors downregulated UCN3 expression . Lack of UCN3 in turn might cause excessive insulin release, contributing to the pathophysiology of diabetes .
Fat depots contribute to peripheral insulin resistance. Male, but not female mice showed increased plasma insulin levels on a fat-rich diet. HFD-fed male mice significantly increased mesenteric and perirenal fat mass depots, but no changes in gonadal or brown fat mass were observed. HFD-fed WT female mice did not show any significant gain in fat mass, whereas Crhr2 null female mice showed significant increases in gonadal, perirenal, and brown fat depots, despite decreasing their HFD consumption. The increase in gonadal fat mass may in part explain why Crhr2 null female mice take longer to conceive than WT females. This observation is consistent with others who report that temporary nutritional stress causes infertility in female mice . Moreover, increase in brown fat depot may explain why female mice are protected from fat-rich diet-induced metabolic phenotypes in this acute period of nutritional stress. Thus, Crhr2 genotype predisposes males and females differently to body and fat mass gain on a fat-rich diet.
Lipid accumulation in livers is another observed phenotype of metabolic syndrome. Non-alcoholic fatty liver is more prevalent in men than women and diet is a known risk factor. Here, we found that Crhr2 genotype is also a sexually dimorphic risk factor for liver fat accumulation. Male mice with Crhr2 genotype showed microvesicular hepatic steatosis on chow diet as well as on a fatty diet. Insulin resistance has been shown to cause hepatic steatosis  although the mechanisms remain to be established [40, 41]. Crhr2 null mice were hyperinsulinemic on a fat-rich diet. Hyperinsulinemia as result of insulin resistance causes hepatic steatosis and deposition of lipid droplets in liver cells due to “selective insulin resistance” [42, 43]. In agreement with other studies , we also found that WT C57BL/6 male mice showed macrovesicular steatosis on a fatty diet, whereas female WT and Crhr2 mice did not show any evidence of hepatic lipid accumulation in this acute phase of fatty diet consumption.
Blood cholesterol, HDL, and LDL levels are known to increase on a fatty diet. In rodents, depending upon several factors, blood triglyceride levels may or may not change on a fatty diet . In our study, blood cholesterol and HDL levels increased in Crhr2 null male, WT male, and female mice on HFD compared with chow-fed controls. Crhr2 null male mice also had elevated calculated LDL levels. Female mice of Crhr2 genotype were protected from HFD-induced dyslipidemia.
Our study is the first to report that downregulation of stress receptors, CRF2, drives metabolic disturbances in response to nutritional stress in a sexually dimorphic manner. Stress receptor dysfunction resulted in aberrant glucose clearance, insulin resistance, increased adiposity, dyslipidemia, and fatty liver in Crhr2−/− male mice. Sex was a significant variable in several outcomes analyzed in this study, with female sex being protective for acute nutritional stress that may be explained by reduced fat-rich diet intake and increased brown fat depots.
Perspectives and significance
Our studies provide insights into how stress that is often coupled with intake of calorie-rich diet or comfort feeding might contribute to development of metabolic syndrome and type 2 diabetes (Fig. 9). Stress does not target one organ or system, but has pleiotropic effects. CRF2 receptor deficiency compromised function in multiple organs. CRF2 receptor dysregulation predisposed male mice that are not obese or overweight, to be at greater risk for developing collective symptoms associated with metabolic syndrome and diabetes. Thus, modulation of stress receptor function in a sex-specific manner may help with therapeutic targeting of metabolic syndrome and associated diseases, such as type 2 diabetes.
- CRF2 :
Corticotropin-releasing factor receptor 2
Gene name for CRF2
Glucose tolerance test
- HPA axis:
Insulin tolerance test
- UCN2 and 3:
Urocortin 2 and 3
Bergmann N, Gyntelberg F, Faber J. The appraisal of chronic stress and the development of the metabolic syndrome: a systematic review of prospective cohort studies. Endocr Connect. 2014;3:R55–80.
Hjemdahl P. Stress and the metabolic syndrome: an interesting but enigmatic association. Circulation. 2002;106:2634–6.
Tao Z, Shi A, Zhao J. Epidemiological perspectives of diabetes. Cell Biochem Biophys. 2015;73:181–5.
Roglic G. World diabetes congress 2015: the Global Health challenges stream: Assessing global progress and results. Diabetes Res Clin Pract. 2015;108:367–8.
Harris RB. Chronic and acute effects of stress on energy balance: are there appropriate animal models? Am J Physiol Regul Integr Comp Physiol. 2015;308:R250–65.
Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol. 2004;44:525–57.
Lai NC, Gao MH, Giamouridis D, Suarez J, Miyanohara A, Parikh J, Hightower S, Guo T, Dillmann W, Kim YC, et al. Intravenous AAV8 encoding Urocortin-2 increases function of the failing heart in mice. Hum Gene Ther. 2015;26:347–56.
Tsuda T, Takefuji M, Wettschureck N, Kotani K, Morimoto R, Okumura T, Kaur H, Eguchi S, Sakaguchi T, Ishihama S, et al. Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction. J Exp Med. 2017;214:1877–88.
Chang J, Hoy JJ, Idumalla PS, Clifton MS, Pecoraro NC, Bhargava A. Urocortin 2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis. Peptides. 2007;28:1453–60.
Hasdemir B, Mhaske P, Paruthiyil S, Garnett EA, Heyman MB, Matloubian M, Bhargava A. Sex- and corticotropin-releasing factor receptor 2- dependent actions of urocortin 1 during inflammation. Am J Physiol Regul Integr Comp Physiol. 2016;310:R1244–57.
la Fleur SE, Wick EC, Idumalla PS, Grady EF, Bhargava A. Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. Proc Natl Acad Sci U S A. 2005;102:7647–52.
Mahajan S, Liao M, Barkan P, Takahashi K, Bhargava A. Urocortin 3 expression at baseline and during inflammation in the colon: corticotropin releasing factor receptors cross-talk. Peptides. 2014;54:58–66.
Gao MH, Giamouridis D, Lai NC, Walenta E, Paschoal VA, Kim YC, Miyanohara A, Guo T, Liao M, Liu L, et al. One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance. JCI Insight. 2016;1:e88322.
van der Meulen T, Donaldson CJ, Caceres E, Hunter AE, Cowing-Zitron C, Pound LD, Adams MW, Zembrzycki A, Grove KL, Huising MO. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat Med. 2015;21:769–76.
Eraslan E, Akyazi I, Erg LEE, Matur E. Noise stress changes mRNA expressions of corticotropin-releasing hormone, its receptors in amygdala, and anxiety-related behaviors. Noise Health. 2015;17:141–7.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120:1640–5.
Fellmann L, Nascimento AR, Tibirica E, Bousquet P. Murine models for pharmacological studies of the metabolic syndrome. Pharmacol Ther. 2013;137:331–40.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition. 1997;13:65 discussion 64, 66.
Lichtenstein AH, Schwab US. Relationship of dietary fat to glucose metabolism. Atherosclerosis. 2000;150:227–43.
Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 2004;53(Suppl 3):S215–9.
Gai Z, Li K, Sun H, She X, Cui B, Wang R. Effects of chronic noise on mRNA and protein expression of CRF family molecules and its relationship with p-tau in the rat prefrontal cortex. J Neurol Sci. 2016;368:307–13.
Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet. 2000;24:410–4.
Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet. 2000;24:403–9.
Kubat E, Mahajan S, Liao M, Ackerman L, Ohara PT, Grady EF, Bhargava A. Corticotropin-releasing factor receptor 2 mediates sex-specific cellular stress responses. Mol Med. 2013;19:212–22.
Moran T: Methods for the study of the controls of food intake in mice. Available at: http://citeseerxistpsuedu/viewdoc/download?doi=10115057476&rep=rep1&type=pdf 2005.
Ingvorsen C, Karp NA, Lelliott CJ. The role of sex and body weight on the metabolic effects of high-fat diet in C57BL/6N mice. Nutr Diabetes. 2017;7:e261.
Laugero KD, Bell ME, Bhatnagar S, Soriano L, Dallman MF. Sucrose ingestion normalizes central expression of corticotropin-releasing-factor messenger ribonucleic acid and energy balance in adrenalectomized rats: a glucocorticoid-metabolic-brain axis? Endocrinology. 2001;142:2796–804.
Pecoraro N, Dallman MF, Warne JP, Ginsberg AB, Laugero KD, la Fleur SE, Houshyar H, Gomez F, Bhargava A, Akana SF. From Malthus to motive: how the HPA axis engineers the phenotype, yoking needs to wants. Prog Neurobiol. 2006;79:247–340.
Hasdemir B, Mahajan S, Oses-Prieto J, Chand S, Woolley M, Burlingame A, Grammatopoulos DK, Bhargava A. Actin cytoskeleton-dependent regulation of corticotropin-releasing factor receptor heteromers. Mol Biol Cell. 2017;28:2386–99.
Catalano KJ, Maddux BA, Szary J, Youngren JF, Goldfine ID, Schaufele F. Insulin resistance induced by hyperinsulinemia coincides with a persistent alteration at the insulin receptor tyrosine kinase domain. PLoS One. 2014;9:e108693.
Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31(Suppl 2):S262–8.
Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852–71.
Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, Herrera PL, Polonsky KS, McGuinness OP, Kulkarni RN. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 2009;9:350–61.
Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest. 1984;74:2296–9.
Salehi A, Vieira E, Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes. 2006;55:2318–23.
Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000;141:111–7.
Hasdemir B, Mahajan S, Bunnett NW, Liao M, Bhargava A. Endothelin-converting enzyme-1 actions determine differential trafficking and signaling of corticotropin-releasing factor receptor 1 at high agonist concentrations. Mol Endocrinol. 2012;26:681–95.
McClure TJ. Infertility in mice caused by nutritional stress before mating. Nature. 1963;199:504–5.
Gluchowski NL, Becuwe M, Walther TC, Farese RV Jr. Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2017;14:343–55.
Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–6.
Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2011;108:16381–5.
Farese RV Jr, Zechner R, Newgard CB, Walther TC. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 2012;15:570–3.
Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7:95–6.
The authors wish to thank Hui Wang for excellent technical help and Dr. Burcu Hasdemir for helpful discussions. The authors also thank Dr. Aras Mattis for help with analysis of liver slides.
This work was funded in part by a NIH grant P30-DK063720 awarded as a pilot grant from UCSF Diabetes Center to AB and DK R56–080787 (AB).
Availability of data and materials
All data are available from the corresponding author upon request.
All animal procedures and care met the NIH guidelines and were approved by UCSF’s Institutional Animal Care and Use Committee.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Crhr2+/− male mice gain more body mass. Line graphs showing weekly change in body mass in male (n = 9/group) and female (n = 9/group) Crhr2+/− mice on chow and HFD. Data is presented as change in body mass per week compared to baseline. (a) Crhr2+/− male mice gained ~ 18.6% body mass on chow and ~ 45% on HFD. (b): Bar graphs showing percent (%) change in body mass for chow- or HFD-fed mice. HFD-fed Crhr2+/− male mice gained ~ 26% more body mass than chow-fed Crhr2+/− mice. (c) Crhr2+/− female mice gained ~ 8.8% body mass on chow and nearly ~ 50.5% on HFD. (d) HFD-fed Crhr2+/− female mice gained ~ 41.7% more body mass than chow-fed Crhr2+/− mice. 3-Way ANOVA and post hoc Tukey’s multiple comparisons as described in main text and figure legends. (DOCX 224 kb)
Weekly food intake in mice. Column bar graphs showing weekly average food intake per mouse in g/ g body weight. (a) Crhr2−/− mice increased chow intake by 25.71% and 36.89% compared with WT and Crhr2+/− mice (n = 8/group) (b) WT female mice consumed 27.57% more HFD per week than Crhr2 null littermates (n = 8/group). 3-Way ANOVA and post hoc Tukey’s multiple comparisons. (DOCX 183 kb)
Crhr2+/− male mice have elevated baseline blood glucose levels. In GTT, blood glucose was measured by tail vein sampling before glucose administration (baseline; 0 min) and at 30, 60, and 120 min after a bolus of intraperitoneal glucose (2 g/kg) injection. Repeated-measure ANOVA followed by Sidak’s post hoc test was used to analyze GTT data. (a) In Crhr2+/− male mice, blood glucose levels were significantly elevated at 0, 30 and 60 min time points on HFD vs. chow. Glucose clearance rate, as reflected by AUC, was not significantly different on HFD- vs. chow. (b) In female Crhr2+/− HFD-fed mice, significant increases in blood glucose levels were noted at 30 only post glucose injection and AUC was higher in HFD-fed vs. chow-fed female mice. (n = 8/group/sex). (DOCX 259 kb)
Blood glucose levels in response to insulin challenge in Crhr2+/− mice. In ITT, blood glucose levels were measured by tail-vein sampling before (baseline; 0 min) and at 15, 30, 45, and 60 min after ip insulin administration in chow- and HFD-fed mice. Repeated-measure ANOVA followed by Sidak’s post hoc test was used to analyze ITT data. (a-b) Male and female Crhr2+/− mice retained normal ITT responses on chow and HFD. n = 8/group/sex. (DOCX 282 kb)
Male mice have increased plasma insulin levels on HFD. Column graphs showing plasma insulin levels in chow- and HFD-fed male and female mice. (a) Significant increases in insulin levels were seen in male WT, Crhr2−/−, and Crhr2+/− mice (HFD vs. chow, n = 9/group). (b) HFD intake did not significantly increase plasma insulin levels in female WT, Crhr2−/−, and Crhr2+/− mice (n = 9/group). Three-way ANOVA and post hoc Tukey’s multiple comparisons. (DOCX 310 kb)
Sex-specific fat mass gain and/or redistribution on chow vs. HFD. Column bar graphs showing fat mass gain over 8 weeks on chow vs. HFD consumption in male and female mice. Four types of fat mass—gonadal (epididymal/ovarian), mesenteric, perirenal, and brown—were assessed. (a) Diet did not change gonadal fat depots in WT and Crhr2−/− male mice, whereas Crhr2+/− mice gained 75.72% more epididymal fat vs. chow. (b) HFD-fed WT and Crhr2−/− male mice increased their mesenteric fat depots by 53.79% and 145.75%, respectively compared with WT chow-fed controls, whereas Crhr2+/− mice showed non-significant increases in mesenteric fat depots vs. chow. (c) HFD-fed WT male mice increased their perirenal fat depots by 32.67% and male Crhr2+/− mice gained 70.68% more perirenal fat mass vs. chow. (d) HFD-fed male Crhr2−/− mice increased their brown fat depots by 253.1% compared with chow-fed WT mice. (e) HFD-fed female Crhr2−/− mice gained 103.91% more ovarian fat vs. chow diet. Female Crhr2+/− mice did not show any significant change in fat mass on HFD compared with any other group. (f) HFD-fed female Crhr2−/− mice increased their mesenteric fat depots by 38% vs. chow. (g) HFD-fed female Crhr2−/− mice increased their perirenal fat mass by 140% vs. chow diet and by ~ 59% compared with HFD-fed WT female mice. (h) HFD-fed female Crhr2−/− mice increased their brown fat depots by 60.86% vs. chow controls. n = 5/group/sex. Three-way ANOVA and post hoc Tukey’s multiple comparisons. (DOCX 530 kb)
Male mice have increased plasma lipid levels. Column bar graphs showing plasma lipid profiles in male and female mice. Plasma cholesterol, HDL, triglycerides, and LDL levels were determined. (a) HFD-fed male WT mice had 37.7%, Crhr2+/− mice had 50.3%, and Crhr2−/− mice had 40.9% higher blood cholesterol levels vs. chow diet. (b) In female WT, Crhr2+/−, and Crhr2−/− mice, HFD consumption resulted in smaller, non-significant increases in blood cholesterol levels vs. chow. (c) HFD-fed male WT mice had 36.1% higher and Crhr2+/− had 38.3% higher HDL levels vs. chow. (d) In female mice, HDL levels did not differ between HFD vs. chow. (e) HFD-fed male Crhr2−/− mice had ~ 53.0% higher calculated LDL levels vs. chow-fed Crhr2−/− and HFD-fed WT mice, whereas Crhr2+/− had 68.0% higher LDL vs. chow. (f) In female mice, diet did not change LDL levels. (g) In male mice, diet did not change triglycerides levels. (h) Female Crhr2+/− mice had significantly elevated triglyceride levels on both chow and HFD compared with WT and Crhr2−/− female mice on chow and on HFD vs. WT chow. n = 8/group/sex. 3-Way ANOVA and post hoc Tukey’s multiple comparisons. (DOCX 524 kb)